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INTRODUCTION 
 The kidney and the skin are the two large networks of the body with their 
abundant blood supply, far in excess of their nutritional demands, the former for 
the constancy of the milieu interior and the latter maintaining mainly 
homeostasis.  No wonder therefore, that they share many diseases and reflect 
mutually one another’s pathology which should be made use of by the clinician.  
Scientific and technologic improvements during the second-half of the 20
th
 
century have provided renal replacement therapy as a life sustaining option for 
many individuals who otherwise might have died.  In each and every year of the 
last decade, the number of individuals with ESRD (end stage renal disease) has 
grown approximately from 20 to 30,000 per year. 
 Cutaneous examination of patients with ESRD has shown that 50 – 100% 
of patients have at least one dermatologic condition.  In addition to ESRD, 
uraemia and conditions associated with renal replacement therapy are fraught 
with numerous and often, relatively unique cutaneous manifestations. 
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AIMS OF THE STUDY 
1. To study the various cutaneous manifestations and their incidence in 
patients with chronic renal failure. 
2. To study the agewise and sexwise incidence of the individual cutaneous 
manifestation. 
3. To study the incidence of cutaneous manifestations in renal transplant 
recipients. 
4. To study the incidence of cutaneous manifestations of associated 
systemic disorder that may contribute to chronic renal failure. 
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REVIEW OF LITERATURE 
Definition: 
 Chronic renal failure is defined as the irreversible, substantial and usually 
longstanding loss of renal function causing ill health usually referred to as 
uraemia.   
 End stage renal disease represents a clinical state in which there is an 
progressive and irreversible kidney dysfunction of a degree sufficient to render 
the patient permanently dependent upon renal replacement therapy (dialysis or 
renal transplantation) in order to avoid life threatening uremia. 
 Uraemia is the clinical and laboratory syndrome reflecting dysfunction of 
all organ systems as a result of untreated or under treated acute or chronic renal 
failure.
[1] 
 
Prevalence and incidence : 
 The true prevalence of chronic renal failure is unknown because many 
patients are asymptomatic or its presence has not been recognized.  The 
prevalence of end-stage renal disease will vary from country to country and will 
depend upon the incidence of particular disease and the availability and capacity 
of dialysis and transplant programs. 
 There are real differences in the incidence of end-stage renal disease 
according to age, gender and race.  In western countries, the incidence is lowest 
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in children and highest in the elderly between 30 and 60 years and is slightly 
higher in males than females.
[2]
  The higher prevalence in developing countries 
may be due to higher incidence of infections leading on to, as well as genetic 
and environmental predisposition and socio-economic factors and access to 
medical care. 
Etiology: 
 Chronic renal failure may be caused by any condition, which destroys the 
normal structure and function of the kidney.  There are many causes of chronic 
renal failure, for most renal diseases can eventually lead to a significant 
reduction in function.
[3]
  
 Review of the 2007 report revealed diabetes mellitus is now responsible 
for close to 50% of new cases of ESRD.  Hypertension and cystic or hereditary 
kidney diseases were the next most common causes.  
Etiology of chronic renal failure :
[3] 
A) Congenital and inherited diseases  
          1. Polycystic kidney  
          2. Alport’s syndrome  
          3. Congenital hypoplasia  
B) Vascular diseases  
          1. Arteriosclerosis (Hypertension) 
          2. Vasculitis (Polyarteritis nodosa, Systemic lupus erythematosus, 
Scleroderma)  
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C) Glomerular diseases 
         1. Proliferative Glomerulonephritis  
         2. Crescentic Glomerulonephritis  
         3. Membranous Glomerulonephritis 
         4. Mesangiocapillary Glomerulonephritis 
         5. Glomerulosclerosis 
         6. Diabetic Glomerulosclerosis 
         7.Secondary Glomerulonephritis (Polyarteritis nodosa, Systemic lupus 
erythematosus, Systemic sclerosis, Wegener’s granulomatosis, Amyloidosis) 
D) Interstitial diseases 
         1. Chronic pyelonephritis 
         2. Vesicoureteric reflux 
         3. Tuberculosis  
         4. Analgesic nephropathy 
         5. Nephrocalcinosis 
         6. Schistosomiasis 
         7. Unknown origin 
E) Obstructive uropathy 
        1. Calculus  
        2. Retroperitoneal fibrosis 
        3. Prostatic hypertrophy 
        4. Pelvic tumors 
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F) Rare causes < 1% of the cases 
        1. Alport’s syndrome 
        2. Hemolytic Uraemic Syndrome 
        3. Metabolic disorders  
Pathophysiology of Chronic Renal Failure:
[4,6] 
 The exact pathogenesis of the clinical syndrome of uraemia is unknown.  
The pathophysiology of uraemic syndrome is attributable to accumulation of 
products of protein metabolism and loss of other renal functions such as fluid 
and electrolyte homeostasis and synthesis of certain hormones (1,25 – 
dihydroxy cholecalciferol).
[5]
  The various uremic toxins
[7]
 are byproducts of 
protein and aminoacid metabolism such as urea, guanido compounds, methyl 
guanidines, urates, hippurates, end-products of aromatic amino acid metabolism 
and other nitrogenous substances, inhibitors of ligand protein binding, 
glucurono conjugates and inhibitors of somatomedin and insulin action.  The 
pathophysiology has been explained based on two hypothesis.  They are as 
follows: 
1. Intact nephron hypothesis : That is most nephrons are non-functioning, 
while the remaining few function normally. 
2. Trade off hypothesis : It is the concept that adaptations arising in 
chronic renal failure may control one abnormality, but only in such a way 
as to produce other changes characteristic of uraemic syndrome.  The best 
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example of ‘trade off’ is increase of parathormone secretion essential for 
increased fractional excretion of phosphate. 
When kidney function is entirely normal, GFR (glomerular filtration rate) can 
be augmented by 20 – 30% in response to the stimulus of a protein challenge.  
As GFR declines to levels as low as 30% of normal, patients may remain 
asymptomatic with only biochemical evidence of the decline in GFR.  As GFR 
falls to below 30% of normal, an increasing number and severity of uremic 
clinical manifestations and biochemical abnormalities supervene.  When GFR 
falls below 5 – 10% of normal, continued survival without renal replacement 
therapy become impossible.
[7] 
Clinical presentation and assessment: 
 In the early stages of the disease, the patient may be asymptomatic and 
the existence of renal insufficiency may be revealed incidentally subsequently 
because of the widespread effects of progressive renal failure, symptoms and 
signs are referable to almost every system.  None of these symptoms alone is 
indicative of underlying renal disease, but the occurrence of more than one 
would suggest the possibility of renal failure. 
Indications of chronicity of renal failure :
[2] 
1. Symptoms : fatigue, breathlessness, anorexia, nausea, vomiting, 
hiccoughs, pruritus, dry skin, bone pain, nocturia, muscle cramps, 
drowsiness, seizures, amenorrhoea, decreased libido. 
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2. Signs : Pallor, pigmentation, increased respiratory rate, hypertension, 
increased jugular venous pulsation, pedal edema, pulsus paradoxus 
(pericardial tamponade), excoriations due to pruritus, brown nails, 
xerosis, paresthesia, absent reflexes. 
3. Investigations : Complete hemogram shows normochromic 
normocytic anemia, increased blood urea and serum creatinine, serum 
electrolytes showing hyperkalemia, hyperphosphatemia, 
hypocalcemia, hyponatremia and low serum bicarbonate, serum 
proteins showing hypoalbuminemia, urinalysis shows proteinuria, total 
24 hrs urine collection for estimating urinary proteins and creatinine 
clearance, urine sediment findings showing RBCs, RBC cast, WBC 
cast, blood sugar, hepatitis B & C viral  detection, Blood VDRL, Anti 
nuclear antibodies, double stranded DNA, c-ANCA, p-ANCA, serum 
complements and imaging studies such as plain X-ray abdomen to 
detect radio-opaque stones or nephrocalcinosis, renal ultrasonogram 
showing small kidneys usually, CT-Scan, MRI, radio-nuclide scan, 
intravenous pyelogram, voiding cysto-urethrogram and renal biopsy. 
Systemic effects of uraemia:
[6] 
The effects of uremia are diverse and almost every system is affected.  
They include cardiovascular, pulmonary, hematologic, neuromuscular, 
gastrointestinal abnormalities, endocrine and metabolic disturbances and the 
most clinching dermatologic abnormalities.  
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Dermatologic abnormalities : 
 Reports indicate that 50 – 100% of patients with end-stage renal disease 
have atleast one cutaneous disorder.
[7]
  The abnormalities affecting the skin may 
be manifested as : 
I. Specific cutaneous manifestations of chronic renal failure. 
II. Skin manifestations due to renal transplantation. 
III. Skin manifestations due to treatment (drugs & dialysis) of renal failure 
(not included in this study). 
I. Specific cutaneous manifestations of CRF: 
 Primary dermatological manifestations associated with uremia are : 
A. Skin changes : 
1. Pruritus : 
Uraemia is the most common metabolic cause of pruritus and pruritus is 
the most common and troublesome cutaneous manifestation of uraemia. 
Incidence :  
 Significant pruritus affects 15 – 49% 
[1]
 of patients with chronic renal 
failure.  Pruritus more commonly begins approximately 6 months after initiation 
of dialysis and typically increases with the length of time on dialysis.   It has  no 
consistent association with age, sex, race or precipitating disease.  Pruritus may 
be episodic or constant, localized or generalized and mild or severe.  The 
axillae, scalp, nose and ears are the most frequent areas of pruritus.  When 
localized, the forearms and upper back are predominantly  affected.
[2]
  Pruritus 
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often worsens at bedtime.  Pruritus is not a feature of acute renal failure.  For 
about 25% of the patients with pruritus, it occurs only during or soon after 
dialysis, and it is more severe at these times for an additional 42% of the 
patients.
[8] 
Etiopathogenesis : 
 Several researchers have concluded that end stage renal disease pruritus is 
multifactorial.
[9,10]
  Some proposed causes of uraemic pruritus include the 
following : 
• Xerosis  – In a study by Kato (2000),
[11]
 the skin water content was 
quantified by using a hygrometer to determine the amount of high 
frequency conductance in the skin surface. Final analysis concluded that 
dialysis patients have less water content in their stratum corneum of their 
skin, but there was no association with pruritus  severity  
• Decreased transepidermal elimination of pruritogenic factors 
• Hyperparathyroidism – results in hypercalcemia and skin calcifications 
which in turn stimulates skin mast cells with consequent release of 
histamine.
[12]
 
• Hyperphosphatemia 
• Hypervitaminosis A
[13]
 – elicit xerotic and pruritic skin in uremic 
individuals not receiving dialysis. Certain patients have been shown to 
exhibit increased levels of retinol.
[14]
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• Increased dermal mast cell proliferation and elevated histamine levels
[15]
 
– mast cells proliferate in renal failure and are known to function as a 
storage and release site for histamine.  Mast cell histamine release plays 
an important role in the pathogenesis of various allergic conditions.  The 
mast cell proliferation theory was refuted when ultra violet light therapy 
was shown to decrease the number of mast cells without a corresponding 
decrease in pruritus. 
• Increased serotonin levels
[16]
  
• Uraemic sensory neuropathy
[17]
 – Johannson, Hlliges and stahle – 
Backdahl (1989),
[18]
 identified and implicated a fine neuron specific 
immunoreactive nerve fibre laden with enolase, an acidic enzyme found 
in neurons, neuroendocrine cells and tumours derived from them. This 
discovery was considered the probable cause for end stage renal disease 
pruritus since the immuno-histochemical stains that demonstrated these 
fibres were not evident in non-pruritic end stage renal disease patients. 
• Middle molecule theory : suggests the retention of unidentified 
pruritogenic substances that accumulate in the dialysis patient since they 
are poorly dialyzable as a result of their molecular size of 300 – 12,000 
dalton.  Beta2 microglobulin, advanced glycosylation end products and 
parathyroid hormones are the middle molecules that have been evaluated, 
but their role is uncertain. 
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Clinical presentation  
i. Normal or xerotic skin 
ii. Excoriations from scratching 
iii. Prurigo nodularis  
iv. Lichen simplex chronicus 
Treatment of pruritus :  
           i) Exclude other clinical causes such as scabies and other non-end stage 
renal disease causes of pruritus and treat it. 
           ii) Regular daily application of emollients reduce xerosis, that contribute 
to pruritus. 
           iii) Augmentation of dialysis efficacy
[15,19]
  
           iv) Normalization of serum calcium and phosphate levels  
           v) Parathyroidectomy 
           vi) UVB therapy
[20]
 – may reduce the epidermal vitamin A content 
[14]
, 
suppress histamine releasing factors in sera of uremic patients and induce 
formation of photoproducts with antipruritic effects. 
PUVA causes reduction in dermal histamine.
[21]
  These form the mainstay of 
therapy.
[14]
  Reduction of skin phosphorous to normal values, possibly through 
an effect of vitamin D.
[22] 
           vii) In dialysis, lowering the Mg concentration of the dialysate.
[23] 
           viii) Cholestyramine (5 g bd)
[24]
 – it binds uric acid  
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            ix) Oral activated charcoal
[26]
 (6g daily x 8 weeks).  By chelation in the 
gut of a circulating toxin.
[25] 
            x) Heparin infusion
[27] 
 is useful in reducing uraemic solutes in blood. 
            xi) IV lidocaine 100 mg – was effective in relieving uremic pruritus for 
upto 24 hrs in some patients.
[28]
  Topical anesthetics such as pramoxine have 
been tried.   
           xii) Nicergoline 30 mg orally Qid + 5 mg IV at dialysis for 2 weeks 
(dopamine agonist)
[29]
  
            xiii) Ketotifen 1 – 2 mg bd (mast cell stabilizer)
[30]
  
            xiv) Transcutaneous electrical needle stimulation, a modified 
acupuncture technique
[31]
 – lateral  inhibition impulses halt itch. 
            xv) Topical capsaicin 0.025%, an irritant cream that depletes substance 
P in peripheral sensory neurons,
[32]
 thereby suppressing itch sensation. 
            xvi) Cimetidine
[33] 
            xvii) Erythropoietin – reduction of plasma histamine concentration.
[34] 
            xviii) Opiate receptor antagonists – naloxone and naltrexone
[35]
 are 
helpful, as endogenous opioids are implicated in the causation of pruritus. 
            xix) Mexiletine
[35] 
            xx) Oral evening primerose oil
[36]
 and topical tacrolimus
[37]
 (0.1% for 2-
6 weeks). 
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2. Xerosis / Ichthyosis: 
 Cutaneous dryness is the most frequent cutaneous abnormality in uremic 
patients.  Significant xerosis occurs for unknown reasons in 50 – 75%
 [39]
 of the 
dialysis population.  When xerosis is associated with desquamation it can cause 
an ichthyosis like appearance.  The extensor surfaces of legs and arms are most 
severely affected with large dark scales whereas over the abdomen, the scales 
are whitish to translucent and somewhat smaller and finer.  The scalp is 
frequently involved with pityriasic desquamation.  The flexor surfaces, the 
axillae and the ante-cubital and the popliteal fossae are relatively spared.  Some 
patients may develop acquired ichthyosis.  Patients with dry skin may also show 
signs of abnormal keratinization or excessive production of keratin such as 
follicular keratosis, onychodystrophy and plantar hyperkeratosis occur even 
without concomitant xerosis.  Xerosis generally appears before initiation of 
dialysis therapy and seems to be little influenced by dialysis.
[38] 
Etiopathogenesis of Xerosis : 
 The pathogenesis is poorly understood .Factors implicated are : 
i. Impairment of exocrine sweat gland secretion with decreased 
sweating.
[39,40]
 
ii. Decrease in water content in the epidermis  
iii. Hypervitaminosis A – plasma and skin content of Vitamin A and its 
carrier, retinol binding protein are increased in uremic patients
[38]
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iv. Increased plasma levels of parathormone with secondary 
hyperparathyroidism. 
v. Disorder in vitamin D metabolism 
vi. Uremia induced alteration in corneocyte maturation. 
Pathology : 
 A reduction in the size of eccrine glands
[40]
 as well as atrophy of 
sebaceous glands.
[39] 
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Electron microscopy: 
 Increased number of corneal cell layers with desmosomal junctions 
present up to the skin surface.  Increased number of keratinosomes showing 
several degrees of alterations.
[38] 
Treatment : 
 There is no specific treatment for uremic xerosis and ichthyosiform 
dermatoses.  Emollients may give symptomatic relief. 
3. Pigmentary alterations : 
 A multitude of uremia related changes are responsible for the pigmentary 
alterations. 
           i. Pallor – it was common before the widespread use of erythropoietin.  It 
is attributed to the significant anemia (reduced erythropoiesis and increased 
hemolysis) 
           ii. Sallow yellow discolouration is attributed to retained urochromes and 
carotene in the epidermis and subcutaneous tissue.
 
           iii. Diffuse hyperpigmentation in sun exposed areas results from an 
increased deposition of melanin in the basal layer of the epidermis and 
superficial dermis.  Due to an increase in poorly dialyzable β melanocyte 
stimulating hormone,
[41,42]
 there is increased melanogenesis with resultant 
deposition of melanin. 
           iv. An increased prevalence of hyperpigmented macules on the palms 
and soles has been reported in a large series of uremic patients.
[43] 
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4. Uraemic frost : 
 First described by Hirschprung in 1865 uremic frost
[38]
 is rarely seen 
today because of early dialytic intervention. 
 It is a classic manifestation of CRF consisting of white amorphous 
deposits on the skin of the face, commonly on beard area, neck and trunk.  It 
dissolves readily when challenged by a drop of water. 
Pathogenesis : 
 When the blood urea nitrogen level is adequately high (usually > 250 – 
300 mg/dl), the concentration of urea in sweat is increased greatly.  Evaporation 
results in the deposition of urea crystals on the skin.
[42] 
5. Perforating disorders: 
 Perforating disorders are seen in 4 – 10% of patients with CRF . They 
may present as four primary perforating disorders: 
i. Kyrle’s disease 
ii. Perforating folliculitis  
iii. Reactive perforating collagenosis 
iv. Elastosis perforans serpiginosa or as  
v. Perforating disorder secondary to uremic follicular hyperkeratosis. 
Pathogenesis : Etiology unclear.  Proposed to be 
 Local trauma (scratching) 
 Dermal microdeposition of substances such as uric acid and calcium 
pyrophosphate or hydroxy apatite followed by an inflammatory response 
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and connective tissue degradation, which allows transepidermal 
elimination of  degraded dermal deposits.
[44,45]
 
 Dysregulation of Vitamin A or Vitamin D metabolism 
 Abnormality of collagen or elastic fibres. 
 Diabetic microangiopathy. 
i. Kyrle’s disease : 
 It has been widely reported to occur in CRF.  Josef  Kyrle first reported it 
in 1916 and called it hyperkeratosis follicularis et parafollicularis in cutem 
penetrans.
[46]
  It has a tendency to affect blacks and it has overwhelming 
coincidence with diabetes mellitus and CRF. 
Clinical criteria
[46]
  described by kyrle are : 
• Chronic generalized papular eruption of size 2 – 8 mm in diameter with 
hyperkeratotic cone – shaped plugs present over extensor aspect of 
extremities. 
• Asymptomatic , follicular or extra follicular lesions. 
• Hyperkeratotic verrucous plaques. 
• Do not involve mucous membrane, palmar or plantar surfaces. 
Histopathological criteria :
[47] 
• Keratotic plug fills an epithelial invagination  
• Focal parakeratosis 
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• Basophilic cellular debris not staining with elastic tissue stains present 
within the plug. 
• Abnormal keratinization of all the epidermal cells including the basal 
cells is present in atleast one region deep to the plug 
 There are numerous reports in literature of various studies in which skin 
lesions satisfying the above criteria having occurred in renal failure.
[46,48,49,50] 
 Thus Kyrle’s disease appears to have a definite association with chronic 
renal failure. 
Treatment:
[51] 
• Topical keratolytics 
• Topical and intralesional glucocorticoids  
• Topical Tretinoin 
• Topical 5 – FU 
• UVB
[44,52] 
• PUVA
[44,52] 
• Cryotherapy 
• Systemic isotretinoin 
• Control of serum phosphorous level 
• Rarely cured after renal transplantation
[53] 
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ii. Perforating folliculitis: 
 It was in 1968 that Mehregan and Cosky
[54]
 first reported perforating 
folliculitis in 25 patients. 
Clinically, perforating folliculitis has the following features: 
• Elevated erythematous follicular papules with central plugs of keratinous 
material over the hairy areas of arms, forearms, thighs and legs. 
• Usually asymptomatic, may be mildly pruritic. 
Histopathological features:
[55] 
- Widely dilated hair follicles plugged by a thick mass of orthokeratotic 
and parakeratotic material. 
- A curled up hair usually cut across is present. 
- Follicular epithelium is disrupted with areas of perforation usually above 
the level of sebaceous  gland, caused by the hair. 
- At sites of perforation, dermis shows a focal inflammatory infiltrate 
containing degenerated collagen and degenerated elastic fibres, which 
have lost their orceinophilic properties and stain brightly eosinophilic.  
However there are no increases in elastic fibres. 
Lesions with both clinical and histopathological criteria have been reported to 
occur in renal failure.
[56,57,58] 
iii Reactive perforating collagenosis :
[55] 
 The acquired form of this inherited disorder clinically characterized by 
umbilicated discrete papules usually over sites of trauma and histologically by 
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cup shaped areas of depression with parakeratotic keratin, basophilic collagen 
and perforation through which collagen is extruded has been reported to occur 
in chronic renal failure.
[59]
  The nosological relationship between reactive 
perforating collagenosis and the acquired perforating dermatosis of renal failure 
still remain uncertain.
[60] 
Pathogenesis : 
 Transepidermal elimination of histochemically altered collagen.
[55] 
iv. Elastosis perforans serpiginosa :
[61] 
 Anecdotal reports of this condition with renal failure are found. 
v. Uraemic follicular hyperkeratosis :
[62] 
 It, described by Garcio and Bravo et al, combines features of Kyrle’s 
disease and perforating folliculitis
[55]
 occurs quite commonly in patients with 
renal failure and patients on dialysis. 
Clinical features : 
 Follicular papules with central keratinous plug, which may coalesce to 
form verrucous plaque present over extensor surfaces of lower extremities. 
Histopathology : 
 Resemble perforating folliculitis with the perforation in the infundibular 
region in small lesions and at the base in larger lesions.  Since the distinction 
between these dermatoses is not clear-cut and there is considerable overlap 
especially in patients with renal failure, it has been proposed to group them 
under a common title of acquired perforating disorder.
[63,64] 
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Treatment : 
 Topical keratolytics, topical glucocorticoids, topical retinoic acid, topical 
5-Fluorouracil,  UVB, control of serum phosphorus level . 
vi. Metastatic calcification :  
 It is a frequent complication of chronic renal failure and occurs when the 
calcium phosphate product exceeds the critical value.  Abnormally elevated 
levels of parathormone may trigger deposition of calcium pyrophosphate in the 
dermis, subcutaneous fat or arterial walls.  Vascular calcification is very 
common in patients with long term chronic renal failure and is seldom 
symptomatic.  Rarely, calcium deposited gives rise to important clinical 
categories of calcinosis cutis and calciphylaxis. 
i. Calcinosis cutis : 
 It is a term used  to describe a group of disorders in which calcium 
deposits are found in the skin.
[65]
  Virchow initially described it in 1855.  
Calcinosis cutis is seen in the setting of chronic renal failure occurring with 
hyperparathyroidism. 
Pathogenesis : 
 Multiple factors in calcium metabolism are affected.  Hyperphosphatemia  
due to decreased renal clearance occur relatively early.  Hypocalcemia occurs as 
a direct result of their hyperphosphatemia and is worsened by renal failure 
induced vitamin D deficiency.  As a compensatory measure, excess parathyroid 
hormone is produced.  This augmentation of parathyroid hormone results in an 
 23
increase in calcium and phosphate mobilization and an elevated solubility 
product and subsequently the formation and precipitation of calcium salts. 
Clinical features : 
 Hard papules, nodules or plaques, which typically occur around large 
joints, may produce a chalky discharge.  This occurs in sub-acute fashion, 
without livedo, or ischemic pain. 
Histopathology: 
 Granules and deposits of calcium are seen in the dermis with or without a 
surrounding foreign body giant cell reaction.  Massive calcium deposits may be 
located in the subcutaneous tissue.  In areas of necrosis, calcium deposition is 
frequently found within the walls of small and medium sized blood vessels.  
Calcium deposition may be confirmed by Von kossa  and Alizarin red stains . 
Treatment : 
Medical : 
a) Dietary measures : Restriction of dietary phosphates and calcium, 
consumption of ketogenic diet including free fatty acids, which causes 
accumulation of keto acids, metabolic products of fatty acids that  
result in decreased pH and thus preventing crystallization. 
b) Magnesium or aluminium antacids may be effective phosphate binders 
in patients with hyperphosphatemia.  However, use in patients with 
renal insufficiency may result in magnesium or aluminium toxicity. 
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c) Probenecid causes increased renal phosphate clearance and 
colchicines (1-1.2 mg/day) act by reducing inflammation associated 
with pruritus.  
d) Intralesional corticosteroid – antiinflammatory and antifibroblastic 
activity. 
e) Sodium etidronate and diphosphonates reduce bone turnover and 
inhibit the growth of ectopic hydroxyapatite crystals.  On prolonged 
treatment paradoxical hyperphosphatemia may result. 
f) Warfarin 
g) Calcium channel blockers – diltiazem (120 mg/day) causes reduction 
in mineral content of calcified tissues.   
Surgery : Excision 
Indications:  
i. Pain 
ii. Recurrent infections  
iii. Ulcerations 
iv. Functional impairment  
Complications : 
 Pain, paraesthesia, ulceration, infection, cosmetic disfigurement, 
mechanical compromise, restricted mobility, vascular occlusion resulting in 
gangrene. 
Prognosis : Excellent  
 25
ii. Calciphylaxis : 
           Synonym : Calcific uremic arteriolopathy 
            It is a highly morbid syndrome characterized by rapidly progressive 
calcification of small and medium sized blood vessels.  Bryant and White first 
reported it in association with uremia in 1898.  It is a rare, serious complication 
of chronic renal failure.
[66]
  The mechanism of  experimental calciphylaxis in 
nephrectomised rats was described by Hans selye, physiologist in 1962.
[67]
  He 
was the first to coin the term calciphylaxis to characterize this enigma. 
Pathogenesis : 
    Factors implicated are : 
 Chronic renal failure 
 Hypercalcemia 
 Hyperphosphatemia  
 Elevated calcium - phosphate products
[68]
  
 Secondary hyperparathyroidism
[69] 
           Selye demonstrated that a series of events might be necessary for the 
formation of calciphylaxis using a rat model.  He defined calciphylaxis as a 
condition of hypersensitivity induced by a set of sensitizing agents in which 
calcinosis occurred only in those subsequently subjected to a group of 
challenges and only after a critical lag time.  Experimental sensitizing events 
and agents included nephrectomy and exposure to parathyroid hormones and 
vitamin D, substances used as challenges - included egg albumin and metallic 
salts.  Calciphylaxis was the end result. 
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Histopathology: 
 Calcification within the media of small and medium sized arterioles with  
intimal hyperplasia.  A mixed inflammatory infiltrate frequently occurs.  
Subcutaneous calcium deposits with panniculitis and fat necrosis may 
sometimes be found.  Vascular microthrombi are frequently evident. 
Clinical features : 
 It may present as a violaceous pattern of livedo reticularis found 
primarily on the trunk and extremities which results in extensive cutaneous 
necrosis. 
Treatment:
[70] 
Medical:  
 Aggravating factors should be addressed and triggering factors should be 
eliminated  
 Dietary alteration (reduction of phosphorous rich foods), non calcium 
containing phosphate binders (Sevelamer or Lanthanum carbonate), 
reduction of dialysate calcium concentration  
 Prevention of superimposed infections with wound care and debridement 
of gangrenous tissue, antibiotics and hyperbaric oxygen 
 Pain management 
Surgical : 
        Total or subtotal parathyroidectomy
[71,72]
 with auto transplantation  
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Complications : 
Ranges from moderate interference of activity to death 
 Non healing ulcers and cutaneous gangrene  
 Amputation 
 Sepsis  
 Gastrointestinal  hemorrhage, infarction and organ failure (heart, brain) 
Prognosis : Grave
[70] 
Mortality rate : 60 – 80% 
[71]
 particularly when the trunk is involved  
Cause of death: 
 Sepsis 
 Organ failure  
Exceptional cases of metastatic soft calcifications presenting as large 
tongue masses
[73]
 or perforating papules
[74]
 have been reported. 
7. Purpura:  
 Purpura, petechiae, ecchymoses are due to mild thrombocytopenia or 
more marked platelet dysfunction and increased vascular fragility
[42]
 or 
associated poor quality collagen. It is partly reversed by dialysis. 
8. Gynecomastia:
[75]  
can  occur  as a  complication  of  hemodialysis 
9. Vascular disorders : 
i. Microangiopathy – severe microangiopathy has been revealed in skin biopsies 
from 75% of patients with chronic renal failure 
[76]
, due to reduction of vascular 
endothelial growth factor. 
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Histopathology: 
 Endothelial cell activation and / or necrosis  
 Basement membrane zone thickening  
 Reduplication of the basal lamina involving both venules and arterioles 
(tend to regress after successful renal transplantation). 
ii. Skin necrosis – Proximal skin necrosis and / or peripheral gangrene may 
occasionally occur in uremic patients. 
 Proximal skin necrosis can involve the trunk, shoulders, buttocks or 
thighs.  Lesions usually spread rapidly covering large areas and have a bad 
prognosis. 
 Distal skin necrosis of the fingers and toes can lead to digital gangrene 
but the disease is usually self-limiting  
9. Poor wound healing is due to decreased collagen turnover caused by chronic 
acidosis 
10. Restless leg syndrome is characterized by burning, painful paresthesia of the 
dorsal or plantar surface of the feet and it is due to peripheral neuropathy
[82]
. 
Treatment is with Dopamine agonists, Gabapentin and Opioids. 
B. Oral mucosal changes : 
 Jaspers has reviewed oral changes, which occurs in uremia.
[77]
  The 
lesions described are :
[78] 
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• Stomatitis is due to chemical burn caused by ammonia released by 
bacteria due to the increased content in the salivary secretion.  The other 
causes are candidial infection and impaired immunity.
[78] 
• Ulcerative stomatitis can occur anywhere in the mouth. 
• Hemorrhagic lesions 
• Hyperkeratosis occurs in long standing renal failure due to the effect of 
toxic chemicals in the oral mucosa.
[77] 
C. HAIR ABNORMALITIES: 
[38] 
They are 
 Loss of hair on forearms and legs  
 Diffuse alopecia of scalp
[79]
 
 Fine dry and brittle hair 
 Trichocalasia and trichorrhexis nodosa 
 Hair discolouration 
                   Microscopic examination of hair in uremia shows hair in telogen 
phase. With scanning electron microscope, uraemic hair shows irregular 
diameter, flattening and twisting of its shaft and mild cuticular abnormalities. 
D. Nail Changes:
 
            It occurs in patients with uremia as well as in those undergoing dialysis.  
Nail changes include:
[80] 
i. Half and half nail 
ii. Brown nail bed arc 
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iii. Mee’s lines 
iv. Muercke’s lines 
v. Terry’s lines  
i. Half and half nail: 
          Synonym : Lindsay’s nails.
[81] 
 Bean first described half and half nails in 1953.  Although not 
pathognomonic of renal failure, they occur in 33% 
[81]
 of patients with azotemia 
and 40% of those on dialysis and disappear several months after successful 
renal transplantation.  Half and half nails are characterized by a dark distal band 
that occupies 20-60% of the nail bed and by a white proximal band.  The distal 
dark band may range in colour from reddish to brown.  Although the condition 
has been observed in toenails, it is more commonly seen in fingernails. 
Causes :
[80] 
 deposition of melanin in the nail plate due to stimulation of matrix 
melanocytes or pink due to normal nail bed. 
 Increase of capillaries and thickening of their walls. 
 Proximal half of  the nail appears white because of edema of the nail bed. 
                Pigment is more visible distally than proximal because of looser 
attachment of the distal nail plate to the nail bed.  The nail changes do not 
correlate with serum calcium, phosphorus or bicarbonate.
[83]
 It is the most 
useful onychopathologic indicator of renal failure. 
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ii. Brown nail bed arc :
[84] 
 Described by Stewart and Raffle as a brown arch affecting the distal part 
of the finger nail bed, just proximal to the point of separation of the nail from its 
bed. 
         Cause is due to lipochromes, which are fat soluble pigments occurring in 
natural fat.(eg: lutein, carotene) 
iii. Mee’s line: 
 Single or multiple transverse white bands, which moves with nail growth. 
It is due to disturbance of nailgrowth at nail matrix. 
iv. Muercke’s lines: 
 Double white transverse horizontal lines that represent an abnormality in 
the vascular bed of the nail. These lines do not move with nailgrowth. 
v. Terry’s nails: 
 These nail changes are fairly specific to chronic renal failure, but may be 
encountered in patients with chronic liver disease and in healthy individuals.  It 
has been applied to nails in which only the distal 20% is normal, which occurs 
due to decreased vascular supply to nailbed. Here the proximal 80% of nail is 
normal and distal end is brownish black. 
vi. Onychodystrophy : 
 Nail plate is thick, dull and opaque with a yellowish, whitish or grey 
color. Rarely, a severe onychodystrophy with spontaneous resolution may 
occur.
[85] 
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II. Skin manifestations due to renal transplantation :  
 The best therapeutic option for many patients with ESRD is renal 
allograft transplantation.  Successful transplantation results in regression of 
many of the metabolic and cutaneous changes of uremia. 
 Studies have shown that 50 – 100% of renal transplant recipients have a 
transplant related cutaneous complaint.  Dermatological disorders associated 
with renal transplantation are a function of the immunosuppressive medications 
prescribed 
[86]
 as well as the immunosuppressed conditions produced. CD 4 
lymphocytopenia occurs due to polyclonal antilymphocyte globulins and 
suppression of cell mediated immunity. Both humoral and cell mediated 
immunity are decreased due to immunosuppressive drugs. Factors such as time 
after transplantation, geographic location, climate and skin type greatly modify 
the clinical disorders associated with renal transplantation. 
 Dermatologic disorders associated with renal transplantation include the 
following: 
I. Medication  related  disorders : 
• Cushingoid changes  
• Gingival hyperplasia  
• Photosensitivity  
• Striae  
• Disorders of the pilosebaceous unit 
      - Acne  
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      - Folliculitis 
      - Hypertrichosis  
      - Keratosis pilaris 
      - Sebaceous gland hyperplasia 
      - Epidermal cysts  
 The specific cutaneous manifestations caused by individual medications 
given after renal transplant include: 
 Calcineurin inhibitors : alopecia, pruritus, acne, gingival hyperplasia, 
hypertrichosis caused by cyclosporine 
 Tacrolimus : alopecia, pruritus, ecchymoses, diaphoresis  
 Corticosteroids : Skin atrophy, telangiectasias, purpura, acne, striae. 
 Sirolimus : acne, oral thrush, oral ulcers, eyelid edema   
 Mycophenolate mofetil : peripheral edema, acne, thrush  
 Azathioprine : aphthous stomatitis, alopecia, hypersensitivity reaction. 
II. Immunosuppression – related disorders:  
 Viral infections  
o Herpes simplex virus  
o Varicella – zoster virus  
o Epstein – Barr virus  
 Bacterial Infections  
o Staphylococcus aureus  
o Bartonella henselae 
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o Mycobacteria  
o Mycobacterium tuberculosis and atypical mycobacteria  
 Fungal infections  
o Superficial mycoses – Dermatophytes, pityrosporum species and 
candidiasis  
o Deep fungal infections – Aspergillus, Cryptococcus, Nocardia and 
Rhizopus species  
o Parasitic infestation – Scabies  
 Premalignant and malignant conditions 
         - Actinic keratoses  
         - Squamous cell carcinoma 
         - Basal cell carcinoma  
         - Keratoacanthoma 
         - Melanoma 
         - Kaposi’s sarcoma 
         - Miscellaneous malignancies- Lymphoma, Merkel cell carcinoma 
(MCC) and dermatofibrosarcoma protuberans. 
Miscellaneous disorders:  
        Transfusion associated graft versus host disease 
        Porokeratosis  
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Medication  related dermatologic disorders:  
 Many cutaneous changes seen in renal transplant recipients are related 
directly to medications used to suppress rejection of renal allograft.  A full 
blown cushingoid appearance develops in 55 – 90%
[86]
 of patients and is 
associated with the high doses of corticosteroids used early after transplantation.  
Cutaneous findings include moon facies, development of a cervical fat pad 
(buffalo hump), striae distensiae, cutaneous atrophy and telangiectasias.  
Changes may resolve or improve when the corticosteroids dose is reduced, 
although they may continue, since steroids are used long term.  Gingival 
hyperplasia, which occurs in approximately one third of patients receiving 
cyclosporin A, tends to occur early and improve over time.
[103] 
 Other cutaneous changes involve poorly understood alterations in the 
pilosebaceous unit and may result from either cyclosporine A or 
corticosteroids.
[86] 
 Acne develops in 15% of patients and primarily affects the chest and 
back.  Most severe in the first year,  acne later improves with reduction of the 
corticosteroid dose.  Sebaceous gland hyperplasia and epidermal cysts are found 
with increased frequency and have been associated with the use of both 
cyclosporin  A and corticosteroids.  Hypertrichosis develops in 60% of patients 
and may be associated with the development of keratosis pilaris. 
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Infections : 
 The iatrogenically induced decrease in cell-mediated immunity 
predisposes the renal transplant recipients to infection by a variety of organisms.  
Patients are at heightened risk of developing oppurtunistic infections during the 
first 6 months after transplantation because of the use of higher doses of 
immunosuppressive agents.
[92] 
Bacterial infections : 
 Patients may develop infections from a variety of acid-fast bacilli, 
specifically typical or atypical mycobacteria.
[86,87]
 Organisms of the 
Mycobacterium fortuitum / Mycobacterium chelonae complex are more 
common causes of AFB cutaneous infections, although others, such as 
Mycobacterium kansasii and Mycobacterium marinum,
[88,90]
 also have been 
reported.  Therapeutic options for these infections include antimicrobials, 
surgical debridement and / or reduction in immunosuppression. 
Fungal infections : 
 Fungal organisms are the most common cause of infection in the renal 
transplant recipients,
[89]
 occurring in 7 – 75%. 
 Pityriasis versicolor has been shown to be the most common fungal 
infection
[86,91]
 and occurs in 18 – 48 % of transplant recipients, which is a higher 
rate than found in the general population.  Colonization of the upper back with 
pityrosporum yeasts has been shown to occur 2 – 3 times more often in the 
transplant recipients, than the general population. 
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 Pityrosporum organisms predispose patients to increased incidence of 
folliculitis.  Dermatophytes although common after renal transplantation, is no 
more common than in the general population.
[88] 
Viral infections : 
 Severe viral infections usually occur during the first year after 
transplantation
[87]
 and predominantly result from herpes viruses.  Infection from 
HPV (human papilloma virus) tend to develop later. Surveys suggest that the 
prevalence of HPV is 15-50% after the first year and increases to 77-95% by 5 
years after transplantation.
[92] 
 Common and plane warts, which predominate, occur most frequently in 
sun-exposed areas and usually are multiple in number.
[93,94]
  HPV 1,2,3 and 4 
are found commonly, although oncogenic types 16 and 18, and types 5 and 8, 
associated with epidermodysplasia verruciformis are also encountered. 
Treatment : 
 Eradication is difficult because the lesions respond poorly to therapy and 
recur frequently. 
 Treating warts early and aggressively is best in transplant recipient 
patients. Using routine modalities such as cryotherapy, electrocoagulation and 
carbon dioxide laser surgery and radiotherapy are not more effective and may 
result in scarring. 
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 Treatment with oral or topical retinoids may be given.  Interferon should 
not be used, as it may trigger allograft rejection.  Imiquimod, when used 
limitedly, is both effective and safe. 
Malignancy : 
 Malignancies are more common after organ transplantation and most are 
primary cutaneous malignancies. 
Incidence : 
 - Non-melanoma skin cancers are 20-40 times greater in transplant 
recipients than in general population. 
 - The incidence increases as the time elapsed after transplantation 
increases because of the duration of immunosuppressive therapy.
[95] 
 - The cumulative risk of cutaneous malignancy is 10 – 30% at 5 years, 10 
– 44% at 10 years and 30 – 40% at 20 years. 
[96] 
Prevalence :  
- of skin cancer varies according to geographic location, amount of UV 
exposure and predominant skin type.   
 Most malignancies occur on sun-exposed areas and usually are found on 
the head, neck  and upper extremites. 
Non-melanoma skin cancer  (NMSC): 
• Squamous cell carcinoma (SCC) is the most common cutaneous 
malignancy and occurs 50 – 250 times 
[96]
 more common than in 
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general population and Basal cell carcinoma (BCC) occurs 6 – 10 
times 
[96]
 more frequently in the renal transplant recipient patients. 
•
 NMSC occur at a younger age in RTRs (renal transplant recipients) 
and are characterized by a more rapid and aggressive course, a 
higher recurrence rate and a greater metastatic potential.
 
• Actinic keratosis show a more severe cytologic atypia, occur at a 
younger age and rapidly progresses to SCC. 
Predisposing factors :  to the development of NMSC includes : 
- exposure to UV rays 
- skin phototype I and II 
- immunosuppression 
- HPV infection 
Management  (of NMSC) include : 
- Sun avoidance  
- Use of broad spectrum sunscreens  
- Early detection of malignant and precancerous lesions  
- Aggressive therapy 
- Complete surgical excision with margin control is necessary. 
- Adjuvant radiotherapy or chemotherapy may have a role in association 
with surgery in certain patients. 
- Imiquimod is safe and effective for superficial BCC and actinic keratoses 
when used on small surface areas. 
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- Chemoprevention using systemic retinoids are used for multiple 
malignancies.  Partial and complete remissions have been reported with 
retinoid use, but long-term therapy is necessary because the beneficial 
effect is lost 2 – 3 months after stopping treatment. 
Kaposi’s sarcoma : 
• Incidence : 400 – 500 times higher than in general population 
• Accounts for approximately 3-5% of transplant – related 
malignancies in RTRs  
• Incidence varies according to geographic regions and is higher in 
Jewish, Mediterranean, Arabic ancestry and in blacks  
•
 Highest incidence is in the first year after transplantation (usually 2 
– 24 months after transplantation)
[95] 
• The development of Kaposi’s sarcoma in RTRs is associated with 
human herpes virus 8. Mucocutaneous lesions occur in 60% of 
patients. 
Treatment: 
- Cessation of immunosuppressive medications  
- Radiotherapy  
- Chemotherapy 
- Excision 
- Cryotherapy 
 
 41
Melanoma: 
- Incidence : Occurs 2 – 9 times more common than in general 
population. 
- Risk of melanoma in RTRs, may include transmission by the 
donor. Studies are conflicting regarding the prognosis of melanoma 
in transplant patients, including the risk of recurrence of melanoma 
following transplantation. 
Other malignancies : 
Malignant fibrous histiocytomas, atypical fibroxanthomas, merkel cell 
carcinoma and dermatofibrosarcoma protuberans have been reported, although 
the incidence of the malignancies are unknown. 
Although lymphomas are the second most common malignancy in 
transplant recipients, cutaneous lymphomas are relatively rare. Cutaneous B-cell 
lymphomas are more common than T-cell lymphomas. 
Miscellaneous disorders: 
- Transfusion associated Graft versus host disease have occurred in patients 
who have received nonirradiated packed red blood cells.  This condition 
usually has a poor prognosis. 
- Porokeratosis, a disorder of epidermal keratinization, has been reported as 
an unusual manifestation of immunosuppression in solid organ transplant 
recipients.  Several of the clinical variants have been reported, including 
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disseminated superficial porokeratosis, single lesions of porokeratosis of 
Mibelli and rare cases of disseminated porokeratosis of Mibelli. 
II. Skin Manifestations due to Treatment of CRF ( Dialysis and drugs): 
1. Pruritus 
2. Xerosis 
3. Pigmentary change – diffuse brown hyperpigmentation, diffuse bluish 
grey discoloration of the skin and nails, acquired hair and skin fairness. 
4. Chronic hemodialysis related porphyria / pseudoporphyria / drug induced 
bullous dermatoses. 
5. Arterio – venous shunt dermatitis 
6. Vascular malformations 
7. Contact dermatitis – both irritant and allergic, may occur to dialysis 
tubing, nickel (needles) and topical medications 
8. Nail changes         – Half and half nails 
    -  Splinter haemorrhages 
    - Onycholysis  
9. Hair Changes - Alopecia  
    - Discoloration of hair 
    - Fine brittle hair 
    - Hair shaft abnormalities 
10. Infections 
11. Pre-malignant conditions  - Multiple actinic keratosis  
      - Porokeratosis 
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12. Malignancy : Basal cell carcinoma 
13. Nephrogenic fibrosing dermopathy 
14. Cutaneous calcinosis in hemodialysis. 
Histopathological changes of uremia in skin: 
They include:
[97] 
Epidermal:  
• moderately thickened stratum corneum  
• reduction of prickle cell layers with cells having pyknotic nuclei 
• vacuolated cytoplasm of the epidermal cells 
• flattening of DEJ 
Dermal : 
• dilatation of the capillaries and lymphatics in mild azotemia  
• dermal atrophy and loss of dermal blood vessels and appendages in 
advanced renal failure. 
Management of renal failure : 
   Management of chronic renal failure falls into 3 distinct parts: 
 Investigations to detect the underlying renal disease and to determine any 
reversible factors which are exacerbating the uremic state. 
 Measures designed to limit adverse effects of loss of renal function and 
when possible to prevent further renal damage 
 In patients with progressive destruction of renal tissue, supportive 
measures in the form of either dialysis or transplant are required. 
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MATERIALS AND METHODS 
 This study was done for 2 years from October 2009 to October 2011 at 
Nephrology OPD, ward and medicine ward, Tirunelveli Medical College 
Hospital, Tirunelveli. Approval was obtained from the institutional ethical 
committee prior to the conduct of this study. 
 During this period, 100 patients who had the presence of skin 
manifestations were selected and studied.  80 patients were known cases of 
chronic renal failure, diagnosed at Nephrology department or medical 
department and 20 patients were renal transplant recipients who were referral 
cases. 
Patient selection: 
Inclusion criteria : 
1. Age : All ages  
2. Sex : Both males and females  
3. Patients with chronic renal failure  
4. Renal transplant patients 
Exclusion criteria : 
1. Patients with HIV infection 
2. Patients with previous malignancies 
3. Drug related cutaneous manifestations  
4. Patients on dialysis 
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 The name, age, sex, address, outpatient, inpatient number were 
noted.  All patients were examined under good light.  Detailed 
patients’ history and dermatological examination including 
cutaneous, scalp, mucosal, palms, soles and nail lesions were done.  
Photographs were taken using Canon digital camera for all 
patients, after informed consent. 
 All patients were thoroughly investigated with routine hematologic 
and biochemical investigations.   
 A thorough history was taken and general examination was done.  
The skin, hair, nails, mucosa were examined thoroughly for 
specific lesions of chronic renal failure, renal transplant related 
skin lesions and associated skin lesions. 
 Selected cases were investigated as follows and treated 
accordingly. 
a) Scraping of skin for direct microscopic examination with 
10% KOH for evidence of superficial mycosis in affected 
patients. 
b) Tzanck smear when indicated in viral infections. 
c) Pus culture and sensitivity 
d) Skin biopsy for HPE in selected cases. 
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OBSERVATIONS AND RESULTS  
 The number of patients studied with chronic renal failure and renal 
transplant were 100. Of these, 80 patients presented with CRF  and 20 were 
renal transplant recipients. 
Statistical analysis:  
        The  study subsets of  CRF and  RTR  were described  and  distributed  in 
respect of their age between the gender by means of averages namely mean. The 
student’s unpaired ‘t’ test was used to interpret the difference of age between 
gender. The specific cutaneous manifestations of CRF and RTR, incidence of 
associated skin lesions and systemic diseases contributing to etiology of CRF 
between the genders were analysed and interpreted by ‘Z’ test of proportions. 
The stastistical software PASW [Predictive and Analysis Soft Ware] statistics -
18 (the so called SPSS) was used for the above statistical procedures. The P 
values less than 0.05 was considered significant under two trial conditions (P < 
0.05) and P value more than 0.05 was considered as non-significant. 
Age incidence : 
 The age of the patients ranged from 16 – 70 years with a mean of 46 
years. The mean age of  CRF cases was 47.9 ± 14.5 [n = 80]  and the mean age 
of  RTR cases was 34.5 ± 11.0 [n = 20] years. The commonest age incidence 
among males and females in CRF patients is between 40 – 60 years and  in 
RTR, it is 20 – 40 years. 
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Sex incidence : 
 Out of 100 patients, 62 were males and 38 were females. Out of 80 CRF 
patients, 47(58.7%) were males and 33(41.2%) were females. Out of 20  RTR, 
15(75%) were males and 5(25%) were females. 
TABLE I 
Age and genderwise distribution of mean ages of study subsets and 
matching between genders : 
Category 
Male Female Difference 
between 
mean 
‘t’ 
test 
d.f 
Signifi
cance n Mean SD n mean SD 
 CRF[Total-80] 47 49.2 14.5 33 46.0 14.6 3.2 0.973 78 P>0.05 
 RT [Total-20] 15 37.1 9.3 5 27.0 13.3 10.1 1.886 18 P>0.05 
 
I.Incidence of specific cutaneous manifestations of chronic renal failure: 
A. Skin 
1. Pruritus :  
 Out of 80 patients, 32(68.1%) males and 15(45.5%) females suffered 
from pruritus.  The total incidence in both sexes was 58.8 %.  20 of these 
patients had excoriations due to pruritus, 2 of them developed prurigo nodularis 
and another 5 developed lichen simplex chronicus. 
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TABLE II 
Incidence of pruritus : 
Gender n 
Incidence of pruritus 
Frequency Percentage 
Male  47 32 68.1% 
Female 33 15 45.5% 
Total 80 47 58.8% 
 
2. Xerosis / ichthyosis :  
 Dryness of skin was noted in 28 (35%) patients, ichthyosis was noted in 
18 (22.5%) patients and acquired plantar hyperkeratosis in 5 (6.2%) patients. 
TABLE III 
Incidence of xerosis/ichthyosis : 
Clinical Features Male = 47 Female = 33 Total = 80 
Frequency Percentage Frequency Percentage Frequency Percentage 
Xerosis 16 34.0% 12 36.4% 28 35.0% 
Ichthyosis 10 21.3% 8 24.2% 18 22.5% 
Plantar 
hyperkeratosis  
4 8.5% 1 3.0% 5 6.2% 
Total 30 63.8% 21 63.6% 51 63.7% 
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3. Pigmentary alterations :  
 Among pigmentary alterations 7 has yellow discoloration, 10 had diffuse 
hyperpigmentation, 5 had hypermelanotic macules of palms and soles and 22 
were pale.  The total number of patients with pigmentary alterations was 44 
(55%). 
TABLE IV 
Incidence of pigmentary alterations : 
Clinical Features Male = 47 Female = 33 Total = 80 
Frequency Percentage Frequency Percentage Frequency Percentage 
Yellow 
discoloration 
4 8.5% 3 9.1% 7 8.7% 
Diffuse 
hyperpigmentation 
8 17.0% 2 6.1% 10 12.5% 
Hypermelanotic 
macules of palms 
and soles 
3 6.4% 2 6.1% 5 6.2% 
Pallor 12 25.5% 10 30.3% 22 27.5% 
Total 27 57.4% 17 51.5% 44 55.0% 
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4. Uremic frost : Not noted 
5. Perforating dermatoses : 
               Clinical morphology of perforating dermatoses is seen in 10 patients. 
With the help of histopathological findings, Kyrle’s disease was seen in 2 
patients, perforating folliculitis in 1 patient.  Others showed features of nodular 
prurigo and prurigo simplex. 
TABLE V 
Incidence of perforating dermatoses : 
 Clinical Features Male = 47 Female = 33 Total = 80 
Frequency Percentage Frequency Percentage Frequency Percentage 
Kyrle’s disease  2 4.2% 0 0.0% 2 2.5% 
Perforating 
folliculitis  
1 2.1% 0 0.0% 1 1.2% 
Others  3 6.4% 4 12.1% 7 8.7% 
Total  6 12.8% 4 12.1% 10 12.5% 
 
6. Metastatic calcification : Not noted 
7. Purpura : over legs were noted in 7 patients, of which the cause was mainly 
due to underlying thrombocytopenia. 
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TABLE VI 
Incidence of purpura : 
Gender N 
Incidence of purpura 
Frequency Percentage 
Male  47 3 6.4% 
Female 33 4 12.1% 
Total 80 7 8.7% 
 
8. Gynecomastia : Not noted  
9. Vascular disorders : Digital gangrene present over toes was noted in one 
patient. 
10. Poor wound healing : following trauma was seen in 3 patients. 
11. Restless leg syndrome : Three patients had burning pain over the soles of 
the feet, of which 1 patient had associated diabetes mellitus. 
B. Mucosal changes : 
 Stomatitis was noted in 14 patients, 3 had oral ulcers and 1 had 
leukokeratosis of oral mucosa.  The total number of patients with mucosal 
changes was 18, and the incidence was 22.5 % 
 52
TABLE VII 
Incidence of mucosal changes: 
Clinical Features Male = 47 Female = 33 Total = 80 
Frequency Percentage Frequency Percentage Frequency Percentage 
Stomatitis  10 21.3% 4 12.1% 14 17.5% 
Oral ulcers 1 2.1% 2 6.1% 3 3.7% 
Leukokeratosis of 
oral mucosa  
1 2.1% 0 0.0% 1 1.2% 
Total 12 25.5% 6 18.2% 18 22.5% 
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C. Hair abnormalities :  
         Diffuse alopecia is seen in 6 patients and 10 had brittle hair.  The total 
number of patients with hair abnormalities was 16.  The incidence was found to 
be 20 % 
Table VIII 
Incidence of hair abnormalities: 
Clinical Features Male = 47 Female = 33 Total = 80 
Frequency Percentage Frequency Percentage Frequency Percentage 
Diffuse alopecia   2 4.2% 4 12.1% 6 7.5% 
Brittle hair 4 8.5% 6 18.2% 10 12.5% 
Total 6 12.8% 10 30.3% 16 20.0% 
 
D. Nail changes : 
 21 (26.2%) had ‘half and half’ nails, 7 (8.7%) had brown nail bed arc.  7 
had shiny nails, 6 had onychodystrophy (nail scraping was done and examined 
under 10% KOH and found to be negative) and 1 had melanonychia.  Other 
features like Mee’s lines, Muercke’s lines and blue nails were not noted. The 
total number of patients with nail changes is 46 (57.5%) 
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TABLE IX 
Incidence of nail changes: 
Clinical Features 
Male = 47 Female = 33 Total = 80 
Frequency Percentage Frequency Percentage Frequency Percentage 
Half and half nails 13 27.6% 8 24.2% 21 26.2% 
Brown nail bed 
arc 
4 8.5% 3 9.1% 7 8.7% 
Shiny nails  2 4.2% 5 15.1% 7 8.7% 
Onychodystrophy 
and onycholysis 
6 12.7% 3 9.1% 9 11.2% 
Melanonychia  0 0.0% 1 3.0% 1 1.2% 
Total 25 53.2% 20 60.6% 45 56.2% 
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SPECIFIC  CUTANEOUS MANIFESTATIONS OF CRF 
TABLE X 
Incidence of specific cutaneous manifestations of CRF: 
Clinical 
features 
Male = 47 Female = 33 
Significance 
Total = 80 
Freq. % Freq. % Freq % 
Pruritus  32 68.1% 15 45.5% P<0.05 47 58.8% 
Xerosis / 
ichthyosis  
26 55.3% 20 60.6% P>0.05 46 57.5% 
Pigmentary 
alterations  
27 57.4% 17 51.5% P>0.05 44 55.0% 
Uremic frost  - - - - - - - 
Perforating 
disorder 
6 12.8% 4 12.1% P>0.05 10 12.5% 
Metastatic 
calcification 
- - - - - - - 
Purpura 3 6.4% 4 12.1% P>0.05 7 8.7% 
Gynecomastia  - - - - - - - 
Vascular 
disorders 
1 2.1% 0 0.0% - 1 1.2% 
Poor wound 
healing  
3 6.4% 0 0.0% - 3 3.7% 
Restless leg 
syndrome 
2 4.3% 1 3.3% P>0.05 3 3.7% 
Mucosal 
changes 
12 25.5% 6 18.2% P>0.05 18 22.5% 
Hair 
abnormalities  
6 12.8% 10 30.3% P>0.05 16 20.0% 
Nail 
abnormalities  
25 53.2% 20 60.6% P>0.05 45 56.2% 
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II. Incidence of skin manifestations specific to renal transplantation : 
Bacterial infections : 
 Furunculosis was seen in 3 patients and infected leg ulcers in 1 patient.  
Pus culture revealed staphylococcus aureus in 2 patients. 
Viral infections : 
 Herpes simplex labialis was seen in 1 patient and 1 patient had herpes 
zoster.  Tzanck smear revealed multinucleated giant epithelial cells.  Verruca 
vulgaris was noted in 4 patients. Incidence of viral infections is found to be 
35%. 
Fungal infections : 
 Pityriasis versicolor was noted in 5 patients.  2 patients had Tinea 
corporis.  Scraping for direct microscopic visualization of fungal elements with 
10% KOH was done and was found to be positive in both cases.  Oral 
candidiasis was seen in 1 patient. Incidence of fungal infections is 40%. 
Parasitic infestations : 
 Scabies was seen in 1 patient. 
Premalignant and malignant lesions were not noted in any patient. 
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TABLE XI  
Incidence of specific cutaneous manifestations of RTR: 
Cutaneous 
Manifestations 
Clinical Features 
Male = 15 Female = 5 
Significance 
Total = 20 
Freq. % Freq. % Freq % 
Bacterial 
infections 
Furunculosis 
2 13.3% 1 20.0% P>0.05 3 15.0% 
 Infected leg 
ulcers 
0 0.0% 1 20.0% - 1 5.0% 
 Total 2 13.3% 2 40.0% P>0.05 4 20.0% 
Viral infections Herpes simplex 
labialis  
0 0.0% 1 20.0% - 1 5.0% 
 Herpes zoster 1 6.7% 0 0.0% - 1 5.0% 
 Verruca vulgaris 3 20.0% 1 20.0% - 4 20.0% 
 Plane wart 0 0.0% 1 20.0% - 1 5.0% 
 Total 4 26.7% 3 60.0% P>0.05 7 35.0% 
Fungal 
infections 
Pityriasis 
versicolor  
4 26.7% 1 20.0% - 5 25.0% 
 Dermatophytosis  2 13.3% 0 0.0% - 2 10.0% 
 Oral candidiasis 1 6.7% 0 0.0% - 1 5.0% 
 Total 7 46.7% 1 20.0% P>0.05 8 40.0% 
Parasitic 
infestations  
Scabies  
1 6.7% 0 0.0% - 1 5.0% 
Pre-malignant 
and malignant 
lesions  
- - - - - - - - 
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III. Incidence of associated skin lesions : 
These were classified as : 
1. Systemic diseases contributing to the etiology of CRF : 
 Skin changes of diabetes mellitus like acanthosis nigricans, perforating 
folliculitis, peripheral neuropathy were noted in 12 patients.  Skin changes of 
SLE like malar rash, erythematous scaly plaques, discoid rash and diffuse 
alopecia of scalp were noted in 2 patients.  Cutaneous findings of scleroderma 
like hide-bound skin, sclerodactyly, salt and pepper pigmentation, and digital 
pitted scars were seen 1 patient. One patient had vasculitic ulcer on lower legs, 
and 1 presented with pupura due to idiopathic thrombocytopenia. 
TABLE XII A 
 Incidence of associated systemic diseases, contributing to etiology of CRF : 
Diseases 
Male = 47 Female = 33 
Significance 
Total = 80 
Freq. % Freq. % Freq. % 
Diabetes 
mellitus  
6 12.8% 5 15.2% P>0.05 11 13.7% 
SLE 0 0.0% 2 6.1% - 2 2.5% 
Scleroderma 0 0.0% 1 3.0% - 1 1.2% 
Vasculitis  0 0.0% 1 3.0% - 1 1.2% 
ITP 1 2.1% 0 0.0% - 1 1.2% 
Total 7 14.9% 9 27.3% P>0.05 16 20% 
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2. Nonspecific cutaneous conditions associated with CRF: 
 Non specific skin diseases associated with these patients were lichen 
planus, psoriasis, erythroderma, eczema with sensitization, stasis eczema, 
vitiligo, phrynoderma, urticaria, seborrheic keratosis, DPN and erythema 
nodosum. 
TABLE XII B 
Incidence of associated skin lesions : (CRF and RTR) 
Diseases 
Male = 62 Female = 38 
Significance 
Total = 100 
Freq. % Freq. % Freq. % 
Lichen planus 3 4.8% 1 2.6% P>0.05 4 4.0% 
Psoriasis 2 3.2% 0 0.0% - 2 2.0% 
Erythroderma 1 1.6% 0 0.0% - 1 1.0% 
Eczema with 
sensitization 
1 1.6% 0 0.0% - 1 1.0% 
Stasis eczema 4 6.4% 3 7.9% P>0.05 7 7.0% 
Vitiligo 6 9.7% 4 10.5% P>0.05 10 10.0% 
Phrynoderma 2 3.2% 1 2.6% P>0.05 3 3.0% 
Urticaria 2 3.2% 3 7.9% P>0.05 5 5.0% 
Seborrheic 
keratosis/ DPN 
6 9.7% 4 10.5% P>0.05 10 1.0% 
Erythema 
nodosum 
1 1.6% 0 0.0% - 1 1.0% 
Total 28 45.2% 16 42.1% P>0.05 44 44.0% 
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DISCUSSION  
 In this study including 80 patients with CRF, the mean age was around 
48, which is in par with the literature of 30 – 60 years.
[2]
  There was a male 
preponderance in this study which goes in par with the literature.
[2]
 The 
commonest age incidence among males and females in CRF patients is between 
40 – 60 years and  in RTR, it is 20 – 40 years. 
I. Specific cutaneous manifestations of CRF : 
A. Skin changes : 
1. Uremic pruritus was seen in 58.8 % and is between the reported ranges of 
50– 90%
[35,87]
  in one study and 40–70%
[98] 
 in another study. It is the 
commonest cutaneous manifestation noted in my study.  
2. Xerosis was seen in 28 patients involving both trunk and extremities. 
Ichthyosis was seen in 18 patients, mostly involving lower extremities. 
Most patients with xerosis also had associated pruritus.  The incidence of 
xerosis/ichthyosis was found to be 57.5 %, which is in par with the 
literature of 50-75%.
[99]
 This is the second commonest cutaneous change 
observed in my study. 
3. Pigmentary alterations : Diffuse pigmentation over sun exposed areas 
which is reported in 60-78%
[100]
 of uremic patients was seen only in 
12.5%  in this study.  Pallor of the skin was seen in  27.5%, which is the 
commonest of pigmentary changes noted in my study. Hypermelanotic 
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macules of the palms and soles were seen in 5 (6.2%)  patients, whereas 
considerable cases have been reported in the literature.
[43]
  The total 
incidence of patients showing pigmentary changes was   55 %.  
4. Perforating dermatoses : This was seen in  10  patients clinically.  Using 
clinical and histopathologic correlation, Kyrle’s disease was found in 2   
patients, perforating folliculitis in 1 patient and features of nodular 
prurigo and prurigo simplex in  7 patients.  The incidence of perforating 
disorders in this study was  3.7  %, which lies near the range of 4-10%
[63]
, 
of patients in the literature.   
5. Purpura was noted in 7 patients, giving an incidence of 8.7%      
Idiopathic thrombocytopenia was the etiology noted in 1 patient. 
 Interesting findings noted were  digital gangrene in 1 patient, poor wound 
healing following trauma in 3  patients and restless leg syndrome in  3 patients. 
 B. Mucosal abnormalities : 
 Oral mucosal lesions were seen in 18  patients with incidence of  22.5 %, 
which is far less than that found in one study.
[101]
 Uremic stomatitis was the 
commonest mucosal change seen in patients with severe end stage renal disease.  
Oral ulcers over the buccal and palatal mucosa were seen in 3 patients.  
Leukokeratosis was seen as whitish plaques in the oral mucosa, in 1 patient.  
Except for the haemorrhagic lesions, all the other oral mucosal changes were 
seen in this study. 
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C. Hair abnormalities : 
 About 7.5 % of the patients reported diffuse loss of hair and  brittle dry 
hair was seen in  10 patients. The incidence of hair abnormalities was  12.5% . 
D. Nail changes : 
 Half and half nails reported to occur in 15-50% 
[83] 
 of uremic patients 
were seen in 26.2 % of patients in this study.  Brown nail bed arc was seen in   
8.7 % as compared to 20 – 45 % 
[84]
 in one study.  Other changes noted are 
shiny nails (probably due to scratching), melanonychia, onycholysis and 
onychodystrophy.  Blue nails, Mee’s lines and Muercke’s lines were not seen. 
 Specific lesions not noted in this study were bullous lesions, uremic frost 
and metastatic calcification. 
II. Skin changes attributed to renal transplantation : 
 Fungal infections (40%) was found to be the most common in this 
study, which is in par with literature.
[86,91]
  Pityriasis versicolor 
(25%) and dermatophytosis (10%)  were the two common 
superficial mycosis noted.  Oral candidiasis was seen in 1  patient. 
 Viral infections were the next highest in incidence, with verruca 
vulgaris (25%) found in significant number of patients, which is 
similar to one study of 20-40% 
[102]
 . Herpes simplex labials and 
Herpes zoster were seen in  5%  of   patients. 
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 Bacterial infections (20%) were low in incidence. Staphylococcus 
aureus was grown in pus culture in 2 of the cases. 
 Classical scabies was seen in 1 patient. 
 The increased incidence of cutaneous infections  could be due to an 
increased susceptibility to infections as a result of impaired 
immunity in these patients.
[87]
   
 There were no cases of premalignant or malignant skin lesions in 
this study. The duration after renal transplantation was between 2 – 
7 years in these patients. Though the onset of malignancies is 10 -
30% 
[96]
 in 5 years of RTR, there were no cases reported in this 
study. 
III. Associated skin lesions : 
 Certain  associated systemic diseases contributed to the etiology of 
renal failure. Skin lesions of systemic lupus erythematosus like 
malar rash, erythematous scaly plaques, atrophic depigmented 
plaques and diffuse alopecia were seen in 2 patients.  Characteristic 
facies with pinched up nose, small mouth, sclerodactyly , salt and 
pepper pigmentation, hidebound skin with digital pitted scars of 
systemic sclerosis was noted in 1 patient.  All of them had renal 
involvement and  provided clue to the etiology of renal failure. 
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 Skin lesions of diabetes mellitus showing acanthosis nigricans was 
seen in  2 patients.  Vasculitic ulcer was seen in 1 patient.  Purpura 
as a clinical manifestation of ITP was noted in 1 patient.   
 Other associated skin lesions were lichen planus, psoriasis, 
erythroderma, eczema with sensitization, stasis eczema, 
phrynoderma, vitiligo, urticaria, seborrheic keratosis and DPN, 
which were coincidental findings. 
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SUMMARY 
 This clinical study of cutaneous manifestations of chronic renal failure 
and renal transplant recipients  done during the period from October 2009 to 
October 2011,  revealed   the following : 
1. Most of the specific cutaneous manifestations of chronic renal failure and 
renal transplantation were noted in this study. Pruritus (58.8%) and xerosis 
(57.5%) were the most common among the specific cutaneous 
manifestations of chronic renal failure, which is similar to another study
[104]
.  
Pigmentary changes (55%) and nail abnormalities (56.2%) were the next.  
Mucosal and hair abnormalities were noted in good percentage of cases.  
Nearly  4 % had perforating dermatosis.  Interesting findings noted in this 
study were digital gangrene, poor wound healing and restless leg syndrome. 
The onset of cutaneous manifestations after CRF ranges between 6 months 
to 3 years in this study. 
2. Skin changes due to renal transplantation were mostly due to infections 
(excluding medication related disorders), with fungal infections (40%) 
being the most commonly noted.  The next to follow was viral infections 
(35%) with verruca vulgaris being the commonest manifestation.  The 
high incidence of cutaneous infections in these patients could be due to 
impaired immunity resulting in increased susceptibility to infections. 
Premalignant and malignant lesions were not noted in this study. After 
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renal transplantation, there is improvement in pruritus in 9 (45%) patients 
and xerosis in 6 (30%) patients. 
3. Skin changes specific to associated systemic diseases helped in finding 
various etiologies of chronic renal failure such as diabetes mellitus, 
systemic lupus erythematosus, scleroderma, vasculitis and ITP . 
4. Other associated skin conditions were not related to etiology and were 
found to be just coincidental. 
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CONCLUSION 
 Pruritus and xerosis were the most common among the specific cutaneous 
manifestations of chronic renal failure, followed by nail abnormalities and 
pigmentary changes.  Calciphylaxis and uremic frost were not noted in any 
patient. The incidence of  hair and nail abnormalities were more among females 
than males in this study.  
 Cutaneous manifestations of renal transplantation were mostly due to 
infections, of which fungal infections were commonly observed followed by 
viral infections.  
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                                                        ABBREVIATION 
 
CRF       -  Chronic Renal Failure 
RT         -  Renal Transplantation  
RTR       -  Renal Transplant Recipients 
ESRD    -  End Stage Renal Disease 
OPD     - Out Patient Department 
DEJ       -  DermoEpidermal Junction 
HPE      -  HistoPathological Examination 
ITP       -  Idiopathic  Thrombocytopenic  Purpura 
SLE      -  Systemic Lupus Erythematosus 
DPN    -  Dermatosis Papulosa Nigra 
DM     -  Diabetes Mellitus 
GFR   -  Glomerular Filtration Rate 
 
 

PROFORMA 
Clinical study of skin manifestations in chronic renal failure and renal 
transplantation 
1. Name : 
2. Age / Sex : 
3. Address : 
4. OP No. : 
5. Category of patients : Cutaneous manifestations   
a. Associated with chronic renal failure  
b. Associated with renal transplantation  
6. Complaints regarding skin manifestations : 
 Complaints Duration Site 
a) Pruritus   
b) Pigmentation   
c) Purpuric spots   
d) Hair changes   
e) Nail changes   
f) Poor wound healing    
g) Any other skin changes   
7. General Examination 
a. anemia 
b. edema 
c. hydration 
d. pulse rate 
e. BP 
f. CVS 
g. RS 
h. P/A 
i. CNS 
j. Fundoscopy 
k. P/R in male 
l. P/V in female 
8. Dermatological Examination: 
a. Cutaneous manifestations specific for renal failure 
i. Skin changes 
1. Pruritus  
2. Pigmentary disturbances  
3. Xerosis / ichthyosis 
4. Perforating dermatosis 
5. Purpura, ecchymoses, haematoma 
6. Metastatic calcification – calcinosis cutis, 
calciphylaxis 
7. Uremic frost 
8. Poor wound healing  
9. Gynecomastia 
10. Scratch marks 
ii. oral mucosal changes 
iii. nail changes 
iv. hair changes 
b. Cutaneous manifestations specific for renal transplantation  
i. Infections 
1. Viral 
2. Bacterial 
3. Fungal 
4. Parasitic  
ii. Premalignant / Malignant lesions  
1. Actinic keratoses 
2. Squamous cell carcinoma  
3. Basal Cell carcinoma 
4. Kaposi sarcoma 
5. Melanoma 
6. Other Malignancies  
c. Other associated cutaneous manifestations  
 
 
9. Investigations  
a. Renal 
i. urine analysis 
ii. urine culture 
iii. blood Hb% 
iv. blood TC 
       DC 
            ESR 
v. platelet count 
vi. blood - urea 
      - sugar 
vii. serum - creatinine 
             - electrolytes  
            - alk. phosphatase 
viii. USG abdomen 
ix. Duplex doppler scan of renal arteries  
x. MR angiography 
xi. renal biopsy 
b. Skin 
i. skin biopsy 
ii. Tzanck smear 
iii. scraping for fungus  - 10% KOH 
- Culture  
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